Back to Search
Start Over
Maximizing oxaliplatin's impact on EGFR + colorectal cancer through targeted extracellular vesicles.
- Source :
- Cancer Nanotechnology (1868-6958); 8/17/2024, Vol. 15 Issue 1, p1-16, 16p
- Publication Year :
- 2024
-
Abstract
- Purpose: To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to epidermal growth factor receptor (EGFR<superscript>+</superscript>) colorectal cancer cells and increase oxaliplatin's cytotoxicity. Method: Oxaliplatin was passively loaded into a stable cell line expressing cetuximab in membranes. EVs were collected and characterized for size, and their ability to target EGFR<superscript>+</superscript> cells was tested. Cytotoxicity experiments were performed, and a xenograft cancer animal model was used to confirm the specific accumulation of oxaliplatin-loaded EVs with cetuximab-expressing membranes in EGFR<superscript>+</superscript> cells. Results: EVs with cetuximab-expressing membranes were successfully produced and used to encapsulate oxaliplatin, resulting in consistently sized oxaliplatin-loaded EVs with cetuximab-expressing membranes. The oxaliplatin-loaded EVs with cetuximab-expressing membranes were specifically accumulated by EGFR<superscript>+</superscript> cells, leading to significant cytotoxic effects on these cells. In the animal model, the oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR<superscript>+</superscript> cells and significantly enhanced oxaliplatin's therapeutic efficacy against EGFR<superscript>+</superscript> cancer cells. Conclusion: EVs with membrane-expressed bioactive molecules are a promising strategy for delivering therapeutic agents to EGFR<superscript>+</superscript> colorectal cancer cells. Highlights: EVs with cetuximab-expressing membranes were used to encapsulate oxaliplatin and target EGFR+ cells. Oxaliplatin-loaded EVs with cetuximab-expressing membranes exhibited significant cytotoxic effects on EGFR+ cells. In a xenograft cancer animal model, oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin's therapeutic efficacy against EGFR+ cancer cells. EVs with targeted membrane expression of drugs are a promising strategy for delivering therapeutic agents to specific cell populations. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 18686958
- Volume :
- 15
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Cancer Nanotechnology (1868-6958)
- Publication Type :
- Academic Journal
- Accession number :
- 179067570
- Full Text :
- https://doi.org/10.1186/s12645-024-00284-0